CERTAIN CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS Russian patent published in 2020 - IPC C07D471/04 C07D487/04 C07D401/12 C07D401/14 A61K31/517 A61K31/519 A61P35/00 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to a novel compound of formula Ia or a pharmaceutically acceptable salt thereof. Compounds have inhibitory activity on EGFR, EGFR L858R, EGFR T790M, EGFR L858R/T790M BTK, KDR or JAK3 and can be used in treating cancer, such as non-small-cell lung cancer, breast cancer, colon cancer, thyroid cancer or ovarian cancer. In formula Ia,

X₁ is CR₂ or N; X₂ is CR₁₁; X₃ is CR₁₂; X₄ is CR₁₃; X₅ is CR₁₄; R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₁₁, R₁₂, R₁₃ and R₁₄ independently represent hydrogen, cyano, halogen, unsubstituted or substituted C₁-C₆ alkoxy, unsubstituted or substituted cycloalkyloxy, unsubstituted or substituted geterotsikloalkiloksi, unsubstituted or substituted C₁-C₆ alkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted amino, unsubstituted or substituted alkoxycarbonyl, or unsubstituted or substituted aminocarbonyl; R₈, R₉ and R₁₀ independently represent hydrogen, cyano, halogen, optionally substituted C₁-C₆ alkoxy, optionally substituted alkoxycarbonyl or E, where at least one of R⁸, R⁹ and R¹⁰ is E; and E is selected from

where alkoxy is -O- (unsubstituted or substituted C₁-C₆ alkyl); alkoxycarbonyl is -(C=O)-(unsubstituted or substituted C₁-C₆ alkoxy); heterocycloalkyloxy is -O-(unsubstituted or substituted heterocycloalkyl); cycloalkyloxy represents -O-(unsubstituted or substituted C₃-C₇ cycloalkyl); aminocarbonyl is -C(=O)-NR^bR^c, where R^b is H, unsubstituted or substituted C₁-C₆ alkyl, unsubstituted or substituted C₃-C₇ cycloalkyl or unsubstituted or substituted heterocycloalkyl; and R^c is hydrogen or unsubstituted or substituted C₁-C₄ alkyl; or R^b and R^c, taken together with the nitrogen atom to which they are bonded, form an unsubstituted or substituted 4–8-member nitrogen-containing heterocycloalkyl, optionally containing 1 or 2 additional heteroatoms selected from O, N and S, in heterocycloalkyl ring; heteroaryl is 5–6-membered aromatic ring containing 1–3 heteroatoms selected from N, O and S; heterocycloalkyl is 3–8-member non-aromatic monocyclic ring containing 1–3 heteroatoms selected from N, O and S; substituted amino is -NHR^d or -NR^dR^e, where R^d is independently unsubstituted or substituted C₁-C₆ alkyl, unsubstituted or substituted C₃-C₇ cycloalkyl or unsubstituted or substituted heterocycloalkyl; and R^e are independently selected from unsubstituted or substituted C₁-C₆ alkyl, unsubstituted or substituted C₃-C₇ cycloalkyl or unsubstituted or substituted heterocycloalkyl; and where substituted alkyl, substituted heterocycloalkyl, substituted heteroaryl and substituted cycloalkyl are substituted with one or more substituents independently representing C₁-C₄ alkyl, C₁-C₄ haloalkyl, -OC₁-C₄ alkyl, -C₁-C₄ alkyl-OH, -C₁-C₄ alkyl-OC₁-C₄ alkyl, -OC₁-C₄ haloalkyl, halogen, -OH, -NH₂, -C₁-C₄ alkyl-NH₂, -N(C₁-C₄ alkyl) (C₁-C₄ alkyl), -NH(C₁-C₄ alkyl), cyano, oxo (as a substitute for cycloalkyl and heterocycloalkyl), -CO₂H, -C(O)OC₁-C₄ alkyl, -CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), -CONH-(C₁-C₄ alkyl), -CONH₂, -NHC(O)-(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)C(O)-(C₁-C₄ alkyl), -C(O)-C₁-C₄ alkyl, -C(O)-C₁-C₄ haloalkyl, -OC(O)-C₁-C₄ alkyl, -SO₂(C₁-C₄ alkyl), -SO₂(C₁-C₄ haloalkyl), -SO₂NH₂, -SO₂NH(C₁-C₄ alkyl), -NHSO₂(C₁-C₄ alkyl) or -NHSO₂(C₁-C₄ haloalkyl).

EFFECT: disclosed are certain chemical compounds, compositions and methods.

67 cl, 7 tbl, 175 ex